Omega Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of debt issuance costs and debt discount
Amortization of operating lease right-of-use assets
Accretion of discounts on marketable securities
Change in fair value of warrant liability
Change in fair value of success fee obligation
Non-cash interest expense
Gain on disposal of fixed assets
Stock-based compensation expense
Deferred rent
Changes in operating assets and liabilities:
Accounts receivable due from related party
Accounts receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Other liabilities
Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of marketable securities
Proceeds from maturities of marketable securities
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of redeemable convertible preferred stock
Payments for preferred stock issuance costs
Proceeds from equity offering
Payments of equity offering costs
Proceeds from initial public offering of common stock, net of commissions and underwriting discounts
Payments for initial public offering costs
Payment of success fee
Proceeds from debt financing
Proceeds from lease financing
Repayment of debt
Payments of financing fees
Proceeds from exercise of stock options
Proceeds from issuance of common stock under equity incentive plans
Net cash provided by financing activities
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash—beginning of period
Cash, cash equivalents and restricted cash—end of period
Supplemental disclosures of cash flow information
Cash paid for interest
Supplemental disclosure of noncash investing and financing activities
Conversion of preferred stock to common stock
Reclassification of warrants to additional paid-in capital
Purchases of property and equipment included in accounts payable and accrued expenses
Fair value attributed to success fee obligation
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents
Restricted cash

Comments